Long Term Therapy With Imatinib: Development of Late Side Effects and Compliance to Treatment
Compliance to Long Term Imatinib Therapy in Newly Diagnosed Patients With Chronic Myeloid Leukaemia.
Sponsor: Imperial College London
Listed as NCT00632255, this observational or N/A phase trial focuses on Chronic Myeloid Leukemia and Newly Diagnosed and remains completed. Sponsored by Imperial College London, it has been updated 7 times since 2008, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Jan 2021 — Jul 2024 [monthly]
Completed
-
Aug 2019 — Jan 2021 [monthly]
Completed
-
Jun 2018 — Aug 2019 [monthly]
Completed
▶ Show 2 earlier versions
-
Apr 2018 — Jun 2018 [monthly]
Completed
Phase: NA → None
-
Jan 2017 — Apr 2018 [monthly]
Completed NA
First recorded
Jan 2008
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Imperial College London
- Novartis Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .